Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
POW ARCHIVE WEEK: Papers: 19 Oct 2019 - 25 Oct 2019
STUDY TYPE:Human Studies, Pharmacology/Drug Development
PAIN TYPE:Itch
DATE PUBLISHED: 2020 Feb
JOURNAL:J Allergy Clin Immunol
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/31629805?dopt=Abstract
Volume:145
ISSUE:2
Atopic dermatitis (AD) is a highly pruritic chronic inflammatory skin disorder. Ruxolitinib, a selective inhibitor of Janus kinase (JAK)-1 and JAK2, potently suppresses cytokine signaling involved in AD pathogenesis.
